tiprankstipranks
Trending News
More News >
Perimeter Medical Imaging Ai Inc (TSE:PINK)
:PINK
Advertisement

Perimeter Medical Imaging AI (PINK) AI Stock Analysis

Compare
19 Followers

Top Page

TSE:PINK

Perimeter Medical Imaging AI

(PINK)

Rating:49Neutral
Price Target:
C$0.50
▲(92.31%Upside)
Perimeter Medical Imaging AI's score reflects strong revenue growth and strategic achievements balanced against significant financial challenges, such as ongoing losses and negative cash flow. While technical indicators suggest bearish trends, positive corporate developments, and strategic advances offset some risks. Continued focus on profitability and capital management is crucial for future improvements.

Perimeter Medical Imaging AI (PINK) vs. iShares MSCI Canada ETF (EWC)

Perimeter Medical Imaging AI Business Overview & Revenue Model

Company DescriptionPerimeter Medical Imaging AI (PINK) is a medical technology company focused on enhancing the accuracy of cancer surgeries through advanced imaging solutions. The company operates primarily in the healthcare and medical technology sectors, offering innovative imaging tools that assist surgeons in identifying cancerous tissues during operations. Their flagship product is an AI-powered imaging platform designed to provide real-time, high-resolution images, aiding in the precise removal of cancerous tissues and potentially reducing the need for repeat surgeries.
How the Company Makes MoneyPerimeter Medical Imaging AI makes money primarily through the sale and leasing of its imaging devices to hospitals and surgical centers. The company also generates revenue from service agreements, maintenance contracts, and by offering training and support for its technology. Additionally, Perimeter may engage in partnerships with healthcare providers and research institutions to expand the application of its technology and drive adoption, which can further contribute to revenue through collaborative agreements and research grants. Key revenue streams include direct sales of imaging devices, recurring revenue from ongoing service and maintenance, and strategic partnerships that enhance their market presence.

Perimeter Medical Imaging AI Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: -33.33%|
Next Earnings Date:Sep 02, 2025
Earnings Call Sentiment Positive
The earnings call demonstrates strong positive momentum with significant revenue growth, successful trial results, and strategic milestones achieved. Despite an increased net loss and the need for additional capital, the overall sentiment is positive due to the promising progress and future potential of the company's products.
Q1-2025 Updates
Positive Updates
Significant Revenue Increase
The company recorded a revenue of $550,000 for the first quarter of 2025, marking a 460% increase over Q1 2024.
Commercial Milestones Achieved
Perimeter achieved multiple commercial milestones including the first capital unit sale, record patient cases, and the highest number of consumables shipped.
Successful Pivotal Trial for B-Series
The pivotal trial for the B-Series OCT system met its primary endpoint with a statistically significant reduction in patients with residual cancer, achieving a margin accuracy of 88.1%.
FDA Pre-Market Approval Application
The company filed a pre-market approval application for the B-Series OCT with the FDA in March 2025 and engaged in positive dialogue with the agency.
Presentation at ASBrS Conference
Dr. Alastair Thompson presented detailed study results of the B-Series pivotal trial at the ASBrS conference, drawing significant attention from researchers and clinicians.
Negative Updates
Increased Net Loss
The company reported a net loss of $4.3 million for Q1 2025, compared to a $2.1 million loss in the same period of 2024.
Need for Additional Capital
Perimeter indicated the need for additional capital to continue executing its growth strategy, with cash and cash equivalents at $2.4 million as of March 31, 2025.
Company Guidance
During the Q1 2025 conference call for Perimeter Medical, the company provided several key financial metrics and strategic updates. The company reported revenue of $550,000 for the quarter ending March 31, 2025, which marked a 460% increase from Q1 2024. Operating expenses remained steady at $4.6 million, while the net loss increased to $4.3 million compared to $2.1 million in the same period in 2024. Cash and cash equivalents stood at approximately $2.4 million, excluding a grant receivable of $931,000. Significant achievements included the first-ever capital unit sale and surpassing $1 million in billings for 2025. The company also expanded into three new states: New Mexico, Tennessee, and Arizona. Strategically, Perimeter is focusing on the commercialization of its FDA-cleared S-Series OCT system and pursuing FDA approval for its B-Series OCT system with ImgAssist AI 2.0, which recently showed promising results in a pivotal clinical trial. The company is also working on broadening its user base and preparing for a potential full commercial launch contingent upon FDA approval of the B-Series.

Perimeter Medical Imaging AI Financial Statement Overview

Summary
The company shows strong revenue growth but continues to face significant profitability challenges, with a high net loss and negative cash flow. The balance sheet is stable with low leverage, but declining equity and assets pose potential risks.
Income Statement
45
Neutral
Perimeter Medical Imaging AI has shown significant revenue growth with a TTM revenue of $1,298,133 compared to $846,194 in the previous year. However, the company continues to operate at a net loss, with a TTM net income of -$15,589,354, indicating ongoing challenges in achieving profitability. The gross profit margin is healthy at 60.6%, but the net profit margin remains negative due to high operating expenses.
Balance Sheet
40
Negative
The company's balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.02, indicating low leverage. However, stockholders' equity has decreased over the past year, and the equity ratio stands at 75.9%. The reduction in total assets and equity might pose potential risks if the trend continues without a corresponding increase in profitability.
Cash Flow
35
Negative
Cash flow analysis shows challenges with a negative free cash flow of -$17,114,155 for TTM, indicating cash burn issues. The operating cash flow to net income ratio is slightly negative, which suggests difficulties in converting operational activities into cash. Despite negative cash flows, the company has managed to secure financing.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue846.19K403.53K132.77K11.34K0.00
Gross Profit535.11K206.42K100.63K5.04K-47.57K
EBITDA-12.64M-17.92M-11.72M-15.95M-6.11M
Net Income-13.39M-18.94M-3.59M-16.76M-8.00M
Balance Sheet
Total Assets14.33M27.09M34.60M9.98M13.16M
Cash, Cash Equivalents and Short-Term Investments6.18M18.43M28.44M5.14M11.70M
Total Debt137.48K192.89K325.68K441.17K400.81K
Total Liabilities3.87M7.10M8.49M2.56M2.40M
Stockholders Equity10.45M15.06M26.11M7.42M10.76M
Cash Flow
Free Cash Flow-16.90M-15.17M-13.86M-16.03M-8.26M
Operating Cash Flow-14.72M-14.70M-11.87M-13.91M-8.26M
Investing Cash Flow-1.90M206.01K-1.75M-1.45M7.24M
Financing Cash Flow8.58M234.47K40.28M10.06M9.84M

Perimeter Medical Imaging AI Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.26
Price Trends
50DMA
0.28
Negative
100DMA
0.37
Negative
200DMA
0.44
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
39.51
Neutral
STOCH
26.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.28, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.51 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PINK.

Perimeter Medical Imaging AI Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
C$132.50M-8.34%0.69%-95.27%
65
Neutral
¥351.06B11.13-2.99%2.50%11.77%-10.16%
61
Neutral
C$26.54M-23.87%18.97%17.57%
54
Neutral
C$239.82M-66.14%51.21%15.33%
49
Neutral
C$25.23M-163.62%245.01%-4.91%
48
Neutral
C$49.66M-291.48%-8.63%7.04%
44
Neutral
C$23.37M207.08%280.56%-7.28%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:PINK
Perimeter Medical Imaging AI
0.24
-0.25
-51.02%
TSE:ASG
Aurora Spine
0.34
0.06
21.43%
TSE:QIPT
Quipt Home Medical
3.05
-2.16
-41.46%
TSE:VPT
VentriPoint Diagnostics
0.14
-0.08
-36.36%
TSE:TLT
Theralase Technologies
0.20
0.04
25.00%
TSE:PRN
Profound Medical
7.98
-7.02
-46.80%

Perimeter Medical Imaging AI Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Medical City Dallas Adopts Perimeter’s Advanced Imaging Technology
Positive
Jul 2, 2025

Medical City Dallas Hospital has adopted Perimeter Medical Imaging AI’s S-Series OCT technology for high-resolution tissue visualization during surgeries. This adoption follows the hospital’s participation in a pivotal trial of Perimeter’s B-Series device, which integrates AI and is under FDA evaluation for breast-conserving surgeries. The S-Series OCT, cleared by the FDA in 2021, offers cellular-level imaging, making it ideal for surgical margin visualization. This deployment marks a significant step in Perimeter’s nationwide technology rollout, potentially enhancing surgical outcomes and positioning the company as a leader in advanced medical imaging solutions.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and Strategy
Perimeter Medical Imaging AI to Present Business Update at Investor Forum
Positive
Jun 10, 2025

Perimeter Medical Imaging AI announced that its CEO, Adrian Mendes, will present an update on the company’s business at the Life Sciences Virtual Investor Forum. This presentation reflects Perimeter’s ongoing efforts to enhance its industry positioning by showcasing its innovative imaging technologies, which aim to address unmet medical needs in cancer surgery.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Perimeter Medical Imaging AI Launches OCT-Tissue Registry to Enhance Surgical AI Technology
Positive
Jun 4, 2025

Perimeter Medical Imaging AI has launched the OCT-Tissue Surveillance Registry to collect images and data from surgeries using their imaging technology. This initiative aims to enhance their AI deep-learning model for investigational technology, potentially improving surgical outcomes and reducing the need for second surgeries. The registry will help in developing a sophisticated AI model by gathering diverse data, which could lead to more personalized patient care and better clinical results.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Perimeter Medical Imaging AI Completes $3.13 Million Prospectus Offering
Positive
Jun 3, 2025

Perimeter Medical Imaging AI, Inc. has successfully closed its prospectus offering, raising approximately $3.13 million through the issuance of over 10 million units. The proceeds will support the commercialization of its technology, clinical evidence establishment, and product development. This financial move is expected to bolster Perimeter’s market position and operational capabilities, potentially enhancing its impact on the medical imaging industry.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Private Placements and Financing
Perimeter Medical Imaging AI Announces $2.5 Million Public Offering
Neutral
May 29, 2025

Perimeter Medical Imaging AI, Inc. has announced the pricing and terms of its public offering of units, aiming to raise at least $2.5 million through the issuance of a minimum of 8,333,334 securities. The proceeds will be used to further commercialize its technology and support product development, with the offering expected to attract U.S. institutional investors and company insiders. The offering is subject to regulatory approvals and is expected to close on or around June 3, 2025, with the potential to raise up to $15 million in total.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and Strategy
Perimeter Medical Imaging AI Partners with Intermountain Health to Study OCT and AI Benefits
Positive
May 23, 2025

Perimeter Medical Imaging AI has partnered with Intermountain Health to explore the clinical, social, and economic benefits of using its OCT and AI technologies to reduce cancer reoperations. This collaboration will initially involve a study on breast-conserving surgery reoperation rates and costs, potentially shaping Perimeter’s commercial and market access strategies. The partnership underscores the commitment to innovation in surgical oncology, with implications for improving patient and provider experiences and expanding the technology’s application beyond breast tissue.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Perimeter Medical Imaging AI Achieves Record Revenue and Advances AI-Enabled Imaging Technology
Positive
May 13, 2025

Perimeter Medical Imaging AI reported record revenue for the first quarter of 2025, driven by significant commercial traction of its FDA-cleared Perimeter S-Series device. The company achieved several commercial milestones, including increased case volumes and substantial billings. Additionally, Perimeter is advancing its next-generation Perimeter B-Series device, which incorporates AI technology, and has submitted a Premarket Approval application to the FDA. The pivotal trial results for the B-Series, presented at the American Society of Breast Surgeons meeting, showed promising outcomes, potentially transforming surgical practices by improving intraoperative decision-making and reducing re-excisions.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Financial Disclosures
Perimeter Medical Imaging AI to Announce Q1 2025 Financial Results
Neutral
May 8, 2025

Perimeter Medical Imaging AI announced it will release its first quarter 2025 financial results on May 13, 2025, followed by a webcast and conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it offers stakeholders insights into the company’s financial health and operational progress, potentially impacting its market positioning and future strategic decisions.

Product-Related AnnouncementsRegulatory Filings and Compliance
Perimeter Medical Imaging AI’s B-Series OCT Achieves Pivotal Trial Success
Positive
May 5, 2025

Perimeter Medical Imaging AI announced successful results from a pivotal trial of its B-Series OCT with ImgAssist AI 2.0, presented at the American Society of Breast Surgeons 2025 meeting. The trial demonstrated a statistically significant reduction in residual cancer during surgery, meeting its primary endpoint and showcasing the device’s potential to improve surgical outcomes by reducing re-excisions and enhancing intraoperative decision-making. The company has submitted a Premarket Approval application to the FDA, marking a significant milestone in its regulatory journey.

Product-Related AnnouncementsBusiness Operations and Strategy
HonorHealth Adopts Perimeter’s Advanced Imaging Technology in Arizona
Positive
Apr 30, 2025

Perimeter Medical Imaging AI announced that HonorHealth is the first healthcare system in Arizona to implement its S-Series OCT technology, enhancing surgical decision-making with real-time, high-resolution imaging of tissue margins. This deployment marks a significant step in Perimeter’s nationwide expansion, increasing access to their technology in a major metropolitan area and reflecting the growing demand for improved surgical outcomes.

Business Operations and Strategy
Perimeter Medical Imaging AI to Present at 2025 Healthcare Investor Conference
Neutral
Apr 28, 2025

Perimeter Medical Imaging AI announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, where it will present updates on its business. This participation underscores Perimeter’s ongoing efforts to enhance its industry presence and communicate its technological advancements, potentially impacting its market positioning and stakeholder engagement.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025